Lindsay et al. established a stochastic mathematical model, parameterized experimental and clinical data, and concluded that the combination therapy of TH-302 and erlotinib was better than single-agent therapy of either in EGFR-mutant NSCLC, which was mainly reflected in delayed drug resistance (Lindsay et al., 2016). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.